Brain 17 Vienna

NOA-4 trial

• Equal response to RT or chemotherapy (PCV or TMZ) as single modality • Better prognosis for patients showing oligodendroglial component (1p/19q co-deletion) and MGMT methylation 1 • A retrospective analysis of the same trial revealed that the addition of chemotherapy was beneficial for IDH1/2 mutated, or IDH1/2 wild type and MGMT methylated 2 1. Wick, et al. JCO, 2009 2. Wick, et al. Neurol, 2013